InterCure Reports Impressive Results for the First Half of 2024
InterCure has announced remarkable revenue figures for the first half of 2024, totaling NIS 126 million. Additionally, the company achieved an adjusted EBITDA of NIS 21 million, which accounts for about 17% of its revenues. These financial results highlight the ongoing success of InterCure's operations and strategic initiatives.
Strong Growth Amidst Challenges
Both the first and second quarters of 2024 ended with positive EBITDAs and operational profits, marking InterCure's 16th and 17th consecutive quarters of profitability. The company's solid performance is particularly impressive given the challenges it has faced, including the effects of recent geopolitical events.
Effects of Recent Events
The revenue figures for this period were impacted by damages from a recent terrorist attack and the ongoing regional conflict. Nevertheless, InterCure is entitled to full compensation from local authorities for both direct and indirect damages sustained at its Southern Facility located in Kibbutz Nir Oz.
Compensation and Recovery Initiatives
So far, InterCure has received tens of millions of NIS in partial advance payments from the authorities, which have helped facilitate the restoration of its damaged facility. The company remains optimistic about its recovery efforts and is dedicated to restoring full operational capacity.
Strategic Partnerships and Future Growth
InterCure has expanded its strategic partnership with Cookies™ to include the German market, with plans to launch Cookies products by the fourth quarter of 2024. This strategic move is part of the company's broader objective to enhance its international presence and product offerings.
Growth Projections
Looking forward, InterCure anticipates achieving double-digit growth in the latter half of 2024 compared to the first half, driven by expected product launches in both the German and UK markets. This growth is supported by the company's commitment to expanding its premium product lines.
Financial Highlights
Alongside its revenue accomplishments, InterCure's operational profit for the first half of 2024 reached NIS 11 million. The company has cash reserves of NIS 21 million and maintains an unused credit line exceeding NIS 22 million. This financial strength positions InterCure well to support its expansion plans and recovery efforts.
CEO's Assurance to Shareholders
Alexander Rabinovitch, the CEO of InterCure, emphasized the company's focus on significant growth opportunities across all territories. The strategic measures taken to enhance cultivation and supply chains in Canada and Europe are crucial for future success. The entry into the German market, supported by Cookies, marks a significant advancement in providing high-quality products to consumers.
About InterCure
InterCure, which trades as Canndoc on NASDAQ and TASE, is recognized as Israel’s largest licensed cannabis producer. The company has established itself as a key player in the pharmaceutical cannabis market by leveraging its distribution network and partnerships while upholding high standards in product quality.
Frequently Asked Questions
What were InterCure's revenue figures for the first half of 2024?
InterCure reported revenues of NIS 126 million during the first half of 2024.
How did recent geopolitical events affect InterCure's operations?
The company experienced revenue impacts from damages related to a terrorist attack and ongoing conflict, affecting its Southern Facility's operations.
What is InterCure's plan for international expansion?
InterCure plans to launch Cookies™ products in Germany in Q4 of 2024 and anticipates double-digit growth in the second half of 2024.
How much cash does InterCure currently have on hand?
The company has reported cash reserves of NIS 21 million, with an unused credit line of over NIS 22 million available for further investments.
What differentiates InterCure in the cannabis market?
InterCure stands out due to its comprehensive seed-to-sale model, robust distribution network, and high-quality pharmaceutical-grade product offerings.